Cargando…

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study

The renal protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors and renin-angiotensin system (RAS) inhibitors on diabetic nephropathy without albuminuria have not been fully investigated. This retrospective cohort study focused on patients with type 2 diabetes mellitus who had a b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishibashi, Tatsuya, Morita, Shuhei, Furuta, Hiroto, Nishi, Masahiro, Matsuoka, Taka-Aki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541410/ https://www.ncbi.nlm.nih.gov/pubmed/37773087 http://dx.doi.org/10.1038/s41598-023-43614-9

Ejemplares similares

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

264 Effective Reduction of Diabetic Nephropathy-Induced Albuminuria With SGLT2 inhibitor Monotherapy
Publicado: (2021)

Thyroid function, glycemic control, and diabetic nephropathy in patients with type 2 diabetes over 24 months: prospective observational study
por: Iwakura, Hiroshi, et al.
Publicado: (2023)

Renal Kallikrein Activation and Renoprotection after Dual Blockade of Renin-Angiotensin System in Diet-Induced Diabetic Nephropathy
por: Zou, Xia, et al.
Publicado: (2015)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
por: Zhang, Lin, et al.
Publicado: (2017)

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats
por: Li, Lei, et al.
Publicado: (2017)

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class
por: Kaneto, Hideaki, et al.
Publicado: (2021)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
por: Kojima, Naoki, et al.
Publicado: (2015)

Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy
por: Qiu, Dan-Dan, et al.
Publicado: (2018)

Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report
por: Morita, Shuhei, et al.
Publicado: (2022)

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
por: Panchapakesan, Usha, et al.
Publicado: (2013)

Renoprotective effects of renin–angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis
por: Cheng, Yiming, et al.
Publicado: (2016)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

2 year followup of patients with diabetes mellitus nephropathy showing albuminuria reversal following angiotensin converting enzyme inhibitors
por: Gopinath, S., et al.
Publicado: (2012)

Aliskiren suppresses the renin–angiotensin–aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial
por: Uzu, Takashi, et al.
Publicado: (2016)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
por: Sackin, Henry
Publicado: (2021)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Severity of arterial and/or arteriolar sclerosis in IgA nephropathy and the effects of renin–angiotensin system inhibitors on its prognosis
por: Sugiura, Naoko, et al.
Publicado: (2021)

A rare case of concomittant pancreatic adenosquamous and neuroendocrine tumours
por: Vial, Izziddine, et al.
Publicado: (2022)

Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
por: Ravid, Mordchai
Publicado: (2009)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

Hypopituitarism and cranial nerve involvement mimicking Tolosa-Hunt syndrome as the initially presenting feature of diffuse large B-cell lymphoma: a case report
por: Kishimoto, Shohei, et al.
Publicado: (2022)

Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?
por: Miyazaki, Hiroki, et al.
Publicado: (2015)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022)

Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients
por: Hase, Michiyo, et al.
Publicado: (2013)

Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation
por: Aoki, Taro, et al.
Publicado: (2020)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis
por: Zhu, Qianqian, et al.
Publicado: (2016)

Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts
por: Mahajan, Kunal, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors and mortality in patients with COVID-19
por: Rossi, Luca, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5728agam97f8tac7ap2gvsik0p